Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06360640
Other study ID # APC148-001
Secondary ID 2023-507939-38-0
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date June 2024
Est. completion date March 2025

Study information

Verified date March 2024
Source AdjuTec Pharma AS
Contact Caroline Hammarström, MSc
Phone 0046 (0) 705292158
Email caroline.hammarstrom@ctc-ab.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this first-in-human trial is to investigate the safety, tolerability, and pharmacokinetics of APC148 after intravenous (IV) infusion of single ascending doses in healthy adults.


Description:

Participants will receive a single 3-hours IV infusion of APC148 or placebo. 6 sequential cohorts are planned. The first 2 subjects in each cohort will be dosed in a sentinel fashion. The subjects will be followed for 7 days.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 46
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Willing and able to give written informed consent for participation in the trial. - Healthy females of non-childbearing potential and healthy males aged =18 and =60 years at the time of the screening visit. - BMI = 18.5 and = 30.0 at the time of the screening visit, and body weight of =50 and =100 kg. - Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG and laboratory values at the time of the screening visit, as judged by the Investigator. - Male participants must be willing to use condom or be vasectomised or practice sexual abstinence from heterosexual intercourse and refrain from donating sperm from the administration of investigational medicinal product (IMP) until 3 months after the administration of IMP. Any female partner of a non-vasectomised male participant who is of child-bearing potential must use a highly effective method of contraception with a failure rate of <1 % to prevent pregnancy from at least 2 weeks prior to the administration of IMP to 3 months after the administration of IMP. - Women of non-childbearing potential. - Adequate renal function at the screening visit: Creatinine estimated glomerular filtration rate (eGFR) =80 mL/min/1.73 m2 for participants aged 18-50 years and eGFR =60 mL/min/1.73 m2 for participants =51 years and S-creatinine = upper limit of normal. Exclusion Criteria: - History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or influence the results or the participant's ability to participate in the trial. - History of kidney disease or renal stone. - Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the administration of IMP. - Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma. - Any planned major surgery within the duration of the trial. - After 10 minutes supine rest at the screening visit, any vital signs values outside the following ranges: - Systolic blood pressure: <90 or =140 mmHg, or - Diastolic blood pressure <50 or =90 mmHg, or - Pulse <40 or >90 bpm - A mean QTcF (QT corrected for heart rate by Fredericia's formula) interval of >450 ms after triplicate measurements. The average of the 3 QTc(F) values will be used to determine the participant's eligibility. - 12-lead ECG: - with PR interval shortening < 120 ms. - PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre- excitation OR - PR interval prolongation > 220 ms OR - Intermittent second or third degree atrioventricular (AV) block, or AV dissociation - History of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome. - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to APC148. - Regular use of any prescribed or non-prescribed medications, including antacids, analgesics, herbal remedies, vitamins and minerals, within 2 weeks prior to the administration of IMP, except occasional intake of paracetamol (maximum 2000 mg/day and not exceeding 3000 mg/week), as well as nasal decongestants without cortisone, antihistamine or anticholinergics for a maximum of 10 days, at the discretion of the Investigator. - Any positive result at the screening visit for serum hepatitis B surface antigen, hepatitis B/C antibodies and/or HIV. - Positive result for drugs of abuse or alcohol at the screening visit or on admission to the trial site prior to the administration of the IMP. - Planned treatment or treatment with another investigational drug within 3 months prior to Day -1. Participants consented and screened but not dosed in previous Phase I trials are not to be excluded. - Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than 3 times/week is allowed before the screening visit. - History of, or current, drug abuse, use of anabolic steroids, alcohol abuse or excessive intake of alcohol, as judged by the Investigator. - Excessive caffeine consumption defined by a daily intake of > 5 cups (1 cup = approximately 240 mL) of caffeine containing beverages, as judged by the Investigator. - Plasma donation within 1 month of the IMP infusion or blood donation (or corresponding blood loss) during the last 3 months prior to the IMP infusion. - Participated in a previous cohort in the trial. - The Investigator considers the participant unlikely to comply with trial procedures, restrictions, and requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
APC148 and Placebo
IV infusion

Locations

Country Name City State
Sweden Clinical Trial Consultants AB Uppsala

Sponsors (2)

Lead Sponsor Collaborator
AdjuTec Pharma AS CTC Clinical Trial Consultants AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and intensity of adverse events (AEs) Frequency, intensity and seriousness of adverse events (AEs) will be assessed. The intensity grades is defined as mild, moderate or severe. AEs will be assessed as not related, possibly or probably related to the investigational medicinal product (IMP) From start of infusion until end of trial visit Day 8
Primary Incidence and intensity of serious adverse events (SAEs) Frequency, intensity and seriousness of Serious adverse events (SAEs) will be assessed. Assessment of causal relationship to IMP will be assessed. From start of infusion until end of trial visit Day 8
Primary Incidence and intensity of infusion-related AEs Frequency, intensity and seriousness of infusion-related adverse events (AEs) will be assessed. The intensity grades is defined as mild, moderate or severe. AEs will be assessed as not related, possibly or probably related to the investigational medicinal product (IMP) From start of infusion until end of trial visit Day 8
Primary Time course of local tolerability reactions The infusion site area will be visually inspected before, during and after the IMP infusion. The assessment will include the Investigator's evaluation of swelling, haematoma, and erythema. In addition, each participant will assess their subjective experience of pain and pruritus. Local tolerability reactions will be recorded as infusion-related Adverse events (AEs) Pre-dose, Day 1, Day 2 and Day 8
Primary Changes from baseline in blood pressure Systolic and diastolic blood pressure and pulse will be measured in supine position after 10 minutes of rest. Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in respiratory rate Respiratory rate will be measured in supine position after 10 minutes of rest. Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in body temperature Body temperature will be measured in supine position after 10 minutes of rest. Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day1, Day 2, Day 3 and Day 8
Primary Changes from baseline in heart rate Heart rate will be measured in supine position after 10 minutes of rest. Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in PQ/PR interval Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. PQ/PR intervals will be recorded. Any values outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in QRS interval Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. QRS intervals will be recorded. Any values outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in QT interval Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. QT intervals will be recorded. Any values outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in QTcF interval Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. QTcF intervals will be recorded. Any values outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in Clinical Laboratory Profile Safety laboratory data, Clinical chemistry, haematology, and coagulation, will be measured. Any values outside of normal ranges will be judged as clinically significant or not clinically significant by the Investigator. Day -1, Day 1, Day 2, Day 3 and Day 8
Primary Changes from baseline in physical examination Assessment of different organ systems. Clinically significant and non-clinically significant abnormal findings will be summarised by treatment and dose. Day -1, Day 1, Day 3 and Day 8
Secondary APC148 plasma concentrations Concentration of APC148 in plasma. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2 and Day 3
Secondary APC148 urine concentrations Concentration of APC148 in urine. Urine samples for the determination of plasma concentrations will be collected. Day 1 and Day 2
Secondary Pharmacokinetic (PK) parameter in plasma - Area under curve (AUC) 0-24 Area under the plasma concentration vs. time curve from time 0 to 24 hours. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - AUC0-inf AUC from time 0 to infinity. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - AUC0-last AUC from time 0 to the last measurable concentration. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - Cmax Maximum observed plasma concentration. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - Tmax Time to Cmax. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - T1/2 Terminal elimination half-life. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - Clearance (CL) Total clearance. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - Vz Volume of distribution. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameter in plasma - Vss determination of plasma concentrations will be collected. Apparent volume of distribution at equilibrium. Venous blood samples (approximately 4 mL) for the determination of plasma concentrations will be collected. Day 1, Day 2, Day 3
Secondary PK parameters in urine - A(e) Urine samples for the amount of unchanged drug excreted into urine (Ae) will be collected. Day 1 and Day 2
Secondary PK parameters in urine - fe Urine samples for the Fraction of IV administered drug that is excreted into urine will be collected. Day 1 and Day 2
Secondary PK parameter in urine - renal clearance (CLr) Urine samples for Renal clearance will be collected. Day 1 and Day 2
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1